Literature DB >> 29718134

The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?

Eric G Meissner1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29718134      PMCID： PMC6117440          DOI： 10.1093/cid/ciy208

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  26 in total

Review 1.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

2.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

4.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 5.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

6.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.

Authors:  J S Bajaj; D M Heuman; P B Hylemon; A J Sanyal; P Puri; R K Sterling; V Luketic; R T Stravitz; M S Siddiqui; M Fuchs; L R Thacker; J B Wade; K Daita; S Sistrun; M B White; N A Noble; C Thorpe; G Kakiyama; W M Pandak; M Sikaroodi; P M Gillevet
Journal:  Aliment Pharmacol Ther       Date:  2014-03-16       Impact factor: 8.171

7.  Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  J Hepatol       Date:  2013-12-25       Impact factor: 25.083

8.  Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.

Authors:  Kosuke Kaji; Hiroaki Takaya; Soichiro Saikawa; Masanori Furukawa; Shinya Sato; Hideto Kawaratani; Mitsuteru Kitade; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

Review 9.  Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.

Authors:  Hiroshi Fukui
Journal:  J Clin Transl Hepatol       Date:  2017-06-29

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240
View more
  1 in total

Review 1.  Intestinal Microbiota-A Promising Target for Antiviral Therapy?

Authors:  Mengling Yang; Yang Yang; Qingnan He; Ping Zhu; Mengqi Liu; Jiahao Xu; Mingyi Zhao
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.